Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Growth: Top line (YoY, sequential), 356% bottom line & More
View:
Post by stockfy on Nov 17, 2021 12:13pm

Growth: Top line (YoY, sequential), 356% bottom line & More

Some short-sighted investors along with some short-term traders sold CZO this morning. Nothing strange. There are always those who are unable to see the big picture. And the big picture is that CZO reported excellent quarterly results for another quarter in a row while the outlook remains bright:


1) Ceapro remains a profitable business with revenue YoY growth and sequential growth.
 
Specifically, Q3 2021 record sales of $4,523,000 compared to $3,476,000 for Q3 2020, representing a 30% increase, while net profit of $875,000 for Q3 2021 versus net profit of $192,000 for Q3 2020, a 356% increase.

 
2) Increased net profit for the third quarter of 2021 comes from improved margin of 65.2% as compared to 47.8% in 2020.


3) Ceapro maintains a fortress balance sheet with zero cash and a lot of cash to fund both organic growth and inorganic growth (acquisitions).


4) With CAD$7.3 million cash and zero debt, Ceapro's Enterprise Value currently is just CAD$37 million.


5) Given that adj. EBITDA in 2021 will be about CAD$5.5 million, CZO trades only 6 times its  adj. EBITDA.

The peers trade above 10 times their adj. EBITDA and many of them lose money.


6) CZO is a takeover target and there is no question about it. 


 
Comment by hoffbag on Nov 17, 2021 12:38pm
The share price is down because Gilles sends a message that he USES the existing business and runs a diatribe on the next dream rather than focusing on what is working and building it.   So PGX-YBG, the next big thing.  Its sooooo AWESOME.  Who is the customer????  What deal is he making?  If this had potential (not saying it doesnt) pharma would be stepping in right ...more  
Comment by stockfy on Nov 18, 2021 3:52am
From Q3 2021 report: "Looking ahead, while considering the ongoing potential economic impact related to COVID-19, evolving consumption trends and escalating inflationary levels we believe Ceapro is well-positioned to once again deliver a strong growth in sales well in line with the positive trend achieved over the last years. While we have experienced a “bump in the road” with the beta ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities